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 25 
Abstract 26 
Albendazole-β-cyclodextrin citrate (ABZ:C-β-CD) inclusion complex in vivo antiparasitic 27 
activity was evaluated in the parenteral phase of Trichinella spiralis infection in mice. An 28 
equimolar complex of ABZ:C-β-CD was prepared by spray-drying and tested in CBi-IGE 29 
male mice orally infected with L1 infective larvae. Infected animals were treated with 50 or 30 
30 mg/kg Albendazole, (ABZ) equivalent amounts of the ABZ:C-β-CD complex and non 31 
treated (controls). Mice received a daily dose on days 28, 29 and 30 post-infection. A week 32 
later, larval burden and percentage of encysted dead larvae were assessed in the host by 33 
counting viable and non-viable larvae in the tongue. Complexation of ABZ with C-β-CD 34 
increased the drug dissolution efficiency nearly eightfold. At 37 days p-i, the reduction 35 
percentage in muscle larval load was 35% in mice treated with 50 mg/kg/day ABZ and 68% 36 
in those given the complex. Treatment with the lower dose showed a similar decrease in 37 
parasite burden. Treated animals showe  a high percentage of nonviable larvae, the 38 
proportion being significantly higher in mice receiving the complex than in control animals 39 
(72-88% vs. 11%, P=0.0032). These data indicate that ABZ:C-β-CD increases bioavailability 40 
and effectiveness of ABZ against encapsulated Trichinella larvae, thus allowing the use of 41 
small doses. 42 
 43 
Keywords: Albendazole:β-cyclodextrin citrate complex; T. spiralis parenteral stages; 44 
antiparasitic activity45 
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1. Introduction 46 
Trichinellosis is a parasitic infection produced by a nematode of the genus Trichinella. This 47 
parasitic disease is a zoonosis emerging and/or re-emerging in several regions of the world. 48 
In Argentina, trichinellosis is mainly caused by Trichinella spiralis and is endemic in pigs, 49 
the major source of human infection [1]. Transmission occurs after ingesting raw or 50 
undercooked meat containing viable L1 infective larvae from pork and pork products 51 
manufactured without the appropriate sanitary controls [2]. Larvae are released from the 52 
nurse cell (due to the gastric digestive fluid pH) and migrate to the intestine; where they 53 
burrow into the intestinal mucosa, mature and reproduce in about 30 hours. Newborn larvae 54 
yielded by the female parasites migrate through blood or lymphatic vessels and reach striated 55 
muscle fibres where they encyst and mature to L1 infective larvae at approximately 30 days 56 
post-infection. The signs and symptoms of the disease are directly related to the number of 57 
ingested larvae. Since its discovery in 1835 by Owen and Piaget [3], this parasitosis could 58 
not be eradicated. There are many factors involved: T. spiralis complex life cycle, its lack of 59 
host specificity, different structural forms and diverse ecological niches throughout the 60 
cycle. Additionally, the acute stage of infection often has no pathognomonic signs and in 61 
most infected people diagnosis is made long after being infected, when larvae have invaded 62 
the skeletal muscle cells. 63 
Currently, the drugs most commonly used for treating trichinellosis are benzimidazole 64 
derivatives such as albendazole, flubendazole, mebendazole, and thiabendazole [4]. 65 
However, when included in conventional pharmaceutical forms, these drugs fail to be 66 
effective to kill muscle encysted larvae [5-7]. Albendazole (ABZ), a benzimidazole 67 
carbamate, is an anthelmintic compound widely used in the treatment of systemic nematode 68 
infections [8]. Nevertheless, its effectiveness is limited by its poor water solubility (1 µg/mL 69 
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at 25 °C) and the consequent low bioavailability, producing in some cases an unpredictable 70 
therapeutic response.  71 
Several strategies may be employed in order to increase solubility, dissolution rate and oral 72 
bioavailability of poorly water soluble drugs, including the formation of complexes with 73 
cyclodextrins (CDs) [9]. These carriers have the ability to form inclusion complexes with 74 
various compounds of low polarity, increasing their apparent solubility. β-cyclodextrin (β-75 
CD) consists of seven glucopyranose units and, owing to its crystalline structure, it shows a 76 
deficient water solubility. The substitution of β-CD hydroxyl groups, the most reactive being 77 
C6-OH and C2-OH, produce very heterogeneous and non crystallizable products. In a 78 
previous work, a non-toxic, water soluble carrier β-CD derivative with citric acid, β-CD 79 
citrate (C-β-CD), was synthesized and physicochemically characterized [10]. C-β-CD 80 
presents acidic groups in its structure that interact strongly with basic drugs such as ABZ, 81 
generating extremely stable inclusion complexes. 82 
Enhanced solubility translates in better bioavailability and should improve the therapeutic 83 
efficacy of orally administered drugs. Thus, the aim of this research work was to evaluate in 84 
vivo the antiparasitic effectiveness of the novel ABZ:β-CD citrate complex (ABZ:C-β-CD) 85 
during the parenteral phase in Trichinella spiralis infected mice. 86 
 87 
2. Materials and methods 88 
2.1. Drug 89 
ABZ (1µg/mL aqueous solubility), β-CD, hydroxypropyl β-CD, and methyl β-CD were 90 
supplied by Sigma-Aldrich Chemie GmbH (Steinheim, Germany). All other chemicals were 91 
of analytical grade. 92 
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 93 
2.2. Drug formulation and physicochemical characterization 94 
The synthesis of C-β-CD was performed as described by Garcia et al. (2014) [10]. Briefly, 95 
the inclusion complexes were prepared by the spray drying method (SD). ABZ (0.56 mol) 96 
was dissolved in acetic acid (10 mL) and then C-β-CD (0.56 mol) and water (20 mL) were 97 
added to the solution. The resulting solution was spray-dried in a Mini Spray Dryer Buchi B-98 
290 (Flawil, Switzerland) under the following conditions: inlet temperature: 130
o
C, outlet 99 
temperature: 70
o
C, air flow: 38 m
3
/h, feed rate 5 mL/min, and aspirator set 100 %. 100 
The dissolution profiles were performed according to the U.S. Pharmacopeia (USP) 101 
conditions, in an USP Standard Dissolution Apparatus Hanson Research SR8 Plus 102 
(Chatsworth, CA), equipped with a rotational paddle (50 rpm). The dissolution medium 103 
(900mL of 0.1N HCl) was maintained at 37 °C. Dissolution efficiency (DE) of the 104 
pharmaceutical dosage form, a concept proposed by Khan and Rookes in 1975 [11] and 105 
defined as the area under a dissolution curve between specified time points, was calculated 106 
using the following equation: 107 
0
100
Dissolution efficiency % (DE) 100
t
y dt
y t

 


  108 
where y is the percentage of dissolved product at time t. 109 
 110 
2.3. Animal model 111 
Adult CBi mice (90-100 days old) of the CBi colony from the Animal Facilities of the 112 
Instituto de Genética Experimental, Facultad de Ciencias Médicas, Universidad Nacional de 113 
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Rosario (from here on CBi-IGE), were used. The CBi-IGE stock comprises five genetically 114 
distinct lines; four of the lines resulted from selection experiments for body conformation 115 
while the fifth (CBi) was the unselected control [12]. The lines are currently in their 128
th
 116 
generation of selective breeding and have a theoretical inbreeding coefficient greater than 117 
0.99. All mice were kept in the same room under identical breeding conditions (23 ± 2 ºC, on 118 
a 12-hour-on/12-hour-off light cycle) and received food (Cargill Laboratory Chow, 119 
pelletized) and water ad libitum. Animals were treated in accordance with the institutional 120 
regulations (National University of Rosario School of Medicine permit number 4978/2013) 121 
which comply with the guidelines issued by the Institute for Laboratory Animal Resources, 122 
National Research Council, USA. 123 
 124 
2.4. Parasite 125 
Trichinella spiralis L1 infective larvae were obtained from donor CBi infected mice. Briefly, 126 
the muscle mass was subjected to artificial digestion at 37ºC in a 1% w/v pepsin - 0.1 N HCl 127 
solution to release the encysted larvae [13]. These were washed and resuspended in sterile 128 
saline solution; from this suspension the infection dose for each animal was prepared by 129 
counting individual larvae. 130 
 131 
2.5. Infection and treatment 132 
CBi males (n=30) were orally infected with two T. spiralis infective L1 larvae per g of body 133 
weight (mean weight 35±3g). After infection, the animals were randomly divided into five 134 
groups (n=6 per group) and were treated with a single daily oral dose of ABZ or ABZ:C-β-135 
CD during the chronic phase of the infection, on days 28, 29 and 30 post-infection. ABZ 136 
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dosage was based on previous studies [14]. Groups I and II received a dose of 50 or 30 137 
mg/kg ABZ; groups III and IV were given, respectively, a dose of the complex equivalent to 138 
50mg/kg or 30mg/kg ABZ; group V, non-treated given the vehicle alone, was used as 139 
control of infection. Treatment efficacy was assessed by comparing muscle larval burden in 140 
treated mice with that in non-treated animals. Both the total number of muscle encysted 141 
larvae and their viability were determined in the tongue of each animal, since this is a 142 
preferred site of encystment in mice [15, 16]. Briefly, mice were sacrificed by CO2 seven 143 
days after administration of the last dose; the tongue was excised, weighed and submitted to 144 
artificial digestion following the method already described. Since the tongue digest has a 145 
small volume, all recovered larvae were counted and the result was expressed as the number 146 
of larvae per g of tissue (relative larval load, RLL). L1 larvae viability in the suspension was 147 
evaluated by a methylene blue vital stain based on the finding that dead and moribund larvae 148 
show alterations in their chitin layer that facilitates the penetration of the dye [17]. One hour 149 
after adding the saline solution, the supernatant was removed and 1mL of 0.5 mg/mL 150 
methylene blue solution in distilled water was added to an equal volume of larvae 151 
suspension. The mixture was incubated for three hours at 37ºC. L1 larvae were then washed 152 
with saline and observed under optical microscopy at 40X magnification. Blue stained 153 
T.spiralis larvae were counted as dead (Fig. 1); this was corroborated by absence of 154 
movement and/or the typical "comma" stance in some larvae. 155 
The reduction percentage in larval burden was calculated for each animal, using the 156 
following formula [14] 157 
    –   “ ” 
Mouse “A” RLL reduction percentage 100
   
control group mean RLL mouse A RLL
RLL control group mean
    158 
 159 
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2.7. Statistical analysis 160 
The statistical significance of the differences in relative larval load among groups was 161 
examined with a one-way analysis of variance, followed by the Bonferroni post-test to 162 
compare pairs of groups [18]. Differences in treatment efficacy was assessed by the non 163 
parametric Kruskall-Wallis test, using Dunn’s test for between groups comparison [18]. 164 
Differences were considered significant if P<0.05. 165 
 166 
3. Results 167 
3.1. Dissolution profiles 168 
Fig. 2 shows the dissolution profiles of ABZ pure drug and ABZ:C-β-CD inclusion 169 
complexes. DE, the parameter derived from the dissolution curves clearly showed an 170 
improvement in the solubility of the complexes compared with the pure drug. DE increased 171 
nearly eightfold when ABZ (11.9 %) was complexed with C-β-CD (95.0 %), demonstrating 172 
the high effectiveness of C-β-CD and the spray drying technique to enhance the drug 173 
dissolution rate. 174 
 175 
3.2. Antiparasitic activity assay in Trichinella spiralis infected mice 176 
Table 1 shows the antiparasitic activity of ABZ:C-β-CD and ABZ pure drug, against 177 
encapsulated larvae. The total number of muscle encysted T. spiralis larvae recovered (RLL) 178 
significantly decreased in treated animals compared with controls (P=0.0057). This 179 
reduction in worm load was observed both in ABZ and ABZ:C-β-CD treated mice 180 
Page 10 of 20
Ac
ce
pte
d M
an
us
cri
pt
10 
 
irrespective of the dose administered, and, though not significantly, was highest in the group 181 
receiving ABZ:C-β-CD 50, 68% vs. 35% attained by the ABZ 50 treated mice.  182 
Besides the observed decrease in the total number of recovered encysted larvae, the 183 
treatment also induced a loss of viability as assessed by the vital stain (Table 1, Fig. 1). 184 
Thus, when both number and viability of recovered larvae were considered, ABZ:C-β-CD in 185 
either dosage reached a 90 % reduction in muscle burden as compared to 79 % obtained with 186 
ABZ. 187 
 188 
4. Discussion 189 
As stated by Dupouy-Camet et al. (2002) [19], anthelmintics must act against all forms of 190 
the parasite and thus in various locations of the body, to be completely effective in treating 191 
trichinellosis, Though usually active during the enteral and migratory stages of the infection, 192 
the current drugs fail to be effective to kill muscle encysted larvae. 193 
ABZ has been shown to be active against the enteral and parenteral phase of the parasite in 194 
experimental trichinellosis but a decline in the parasite drug sensitivity was observed during 195 
the invasive and encystment phase [20]. The results described herein confirm that ABZ pure 196 
drug has a relatively low antiparasitic activity against encysted larvae. Treatment with ABZ 197 
had an efficacy comparable to that reported by López-García et al. (1997) [21] who treated 198 
mice with 50 mg/kg/day ABZ from days 34 to 36 p-i. These authors concluded that ABZ is 199 
efficacious against T.spiralis encysted larvae if given at a dose of 100 mg/kg/day (94.7% 200 
reduction). Li et al. (2012) [22] came to a similar conclusion, recommending a dose of 250 201 
mg/kg/day against encapsulated T. spiralis larvae. Moreover, the anthelmintic effects of a 202 
single treatment did not improve by repeated treatment (50, 75 or 100 mg/kg/day for three 203 
days, beginning on day 34 p-i) as the efficacies were always lower or identical to those of a 204 
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single treatment at the corresponding doses [23]. At variance with those reports, mice treated 205 
with 20 mg/kg/day for longer periods, from days 30 to 60 p-i, achieved a 70% decrease in 206 
muscle larval burden [6]. Altogether, these reports indicate the need for high dosage and/or 207 
long treatment periods to improve the antiparasitic efficacy of ABZ against encysted T. 208 
spiralis larvae. 209 
The results of the present study showed that ABZ complexed with the novel derivative of β-210 
cyclodextrin, β-cyclodextrin citrate, is more efficient than ABZ alone against the parenteral 211 
stages of T. spiralis larvae. Larval burden on day 37, seven days after administering the last 212 
dose, was significantly reduced, possibly because larvae cysts were damaged and rapidly 213 
destroyed due to a better distribution of the drug in blood and tissues. Similarly, 2-214 
hydroxypropyl β-cyclodextrin inclusion complexes of ABZ [24] or a benzimidazole 215 
derivative [25] had a better anthelmintic activity than the pure drug, probably as a 216 
consequence of the increased solubility of the drug in the complex. 217 
The finding of a significantly increased proportion of dead worms in the larvae recovered 218 
from mice treated with the ABZ:C-β-CD complex also suggests the greater efficacy of the 219 
formulation compared with the pure drug. The enhanced effectiveness was probably a 220 
consequence of improved drug bioavailability resulting from the increased solubility and 221 
dissolution rate, which lead to a better absorption. It had been reported that plasma 222 
concentration of the active metabolite ABZ-sulphoxide is significantly increased when an 223 
ABZ-β-CD complex is given to mice in a model for Trichinella infections [26]. 224 
Improving oral absorption of poorly soluble drugs has focused on supersaturating delivery 225 
systems to induce its precipitation in the gastrointestinal tract [27, 28] thus enhancing 226 
bioavailability and therapeutic efficacy. Super-saturation is a thermodynamically metastable 227 
state that enforces the precipitation. Appropriate evaluation of super-saturation, precipitation 228 
and possibly precipitation inhibition is concluded for the efficient development of new 229 
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pharmaceutical formulations. Moreover, the results described herein, as well as those by 230 
others [6, 21, 22] indicate that administration of high doses to enhance ABZ oral absorption 231 
does not improve the antiparasitic efficacy of the drug against encysted larvae and has the 232 
disadvantage of accentuating its typical side effects. 233 
It is worth mentioning that the results herein described were obtained after a short treatment 234 
and using small doses of the ABZ:C-β-CD inclusion complex, similar to those recommended 235 
for the treatment of human trichinellosis. This treatment protocol was as effective as the 236 
higher doses or longer treatment periods proposed by other authors. Moreover, it has the 237 
advantage that should be accompanied with a decrease in serious adverse effects. Thus, the 238 
proposed system shows promising results to treat the parenteral stage of T. spiralis infection. 239 
240 
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Figure captions 304 
Fig. 1. T. spiralis L1 larvae micrograph showing a dead larvae (arrow) stained with 305 
methylene blue. Magnification 40X. 306 
 307 
Fig. 2. Dissolution profile of 100 mg ABZ pure drug and the same dosage of ABZ:C-β-CD, 308 
molar ratio 1:1. Test conditions were 0.1N HCl at 37 ºC. Each point represents the mean of 309 
three measurements ± one standard deviation. Open circles (ABZ, pure drug) filled circles 310 
(ABZ:β-CD). 311 
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Table 1. Effect of decreasing doses of ABZ and ABZ:C-β-CD on muscle relative larval load* (RLL) in T. spiralis infected CBi mice  
Drug 
ABZ dosage 
(mg/kg bw) 
RLL' Drug efficacy# 
Total Dead larvae 
RLL 
reduction percentage 
Dead larvae 
percentage 
ABZ 
50 795 ± 145.7
a 
464± 103.7
a 
35 (0-70)
a 
57 (35-95)
a,b 
30 634 ± 103.5
a 
381 ± 48.8
a 
52 (17-72)
a 
69 (39-84)
a,b
 
ABZ:C-β-CD 
50 511 ± 109.7
a 
333± 83.6
a,b 
68 (29-82)
a 
72 (31-100)
b 
30 766 ± 154.2
a 
552± 46.5
a 
51 (0-66)
a 
88 (54-100)
b 
Control --- 1226 ± 98.6
b 
132 ± 25.9
b 
--- 11 (5-21)
a 
' Mean ± SEM                                   #Median (range) 
Differences among groups were evaluated by a one-way ANOVA, using Bonferroni’s post-test for comparisons between groups (Relative 
larval load), or by the nonparametric Kruskall–Wallis test, and Dunn’s test for between groups comparison (Larval load reduction 
percentage and Dead larvae percentage). 
For each variable, differences between groups not sharing the same superscript are significant at the 0.05 level. 
*Larval load was measured in the tongue, a preferred site of encystment in mice. 
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